Superiority of this form of MUC1 over carbohydrate antigen 19-9 (CA19-9) and CEA was proven, when used for the purpose of differential diagnostics of benign and malignant diseases of the biliary pathways, as well as for stage I and II carcinomas [151]. This evidence concerns the gene MUC1 and carcinoma.